STAT-Diagnostica closes $28.5m financing for launch of DiagCORE near patient testing system

Spanish medical diagnostics company STAT-Diagnostica has completed a $28.5m Series C financing to support the launch of its DiagCORE near patient testing system in Europe next year.

Free Report

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:

Macroeconomic and demographic environment
Consumer context
Industry environment
Competitive environment
Route to market

Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.

By GlobalData

By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The DiagCORE is an integrated molecular and immunoassay diagnostics system designed to operate in near patient testing (NPT) environments for acute care settings.

It can cater to the NPT for low-test volumes or as a platform to cover medium requirements for small and large-sized hospitals.

"STAT-Diagnostica’s DiagCORE system can become the best-in-class platform for decentralised molecular testing, the most attractive growth area in molecular diagnostics today."

DiagCORE is said to facilitate faster test turnaround times from sample to results and is aligned to clinical laboratory improvement amendments (CLIA) guidelines.

The process can be conducted in one step and can be performed on a range of samples on a single platform including whole blood, swabs, bronchoalveolar lavage (BAL), stool, sputum and offer up to 48-multiplex capabilities via real-time polymerase chain reaction (PCR).

The time taken to produce results can be as short as 30 minutes but up to 80 minutes, depending on the assay type.

DiagCORE’s performance is expected to improve clinical decision making and enhance the delivery of better patient management and at the same time save costs incurred by the healthcare system.

New investor in the financing programme Gilde Healthcare partner Arthur Franken said: "STAT-Diagnostica’s DiagCORE system can become the best-in-class platform for decentralised molecular testing, the most attractive growth area in molecular diagnostics today."

STAT-Diagnostica will implement DiagCORE on a range of decentralized testing environments, including critical care and emergency medicine units within hospitals. The system will also be incorporated with CLIA-waivable features that will enable it to be used in clinics and physician offices.